Aurobindo Pharma arm Apitoria Pharma appoints new CEO, Independent Director

Published On 2023-04-06 05:30 GMT | Update On 2023-04-06 07:00 GMT

Telangana: Aurobindo Pharma has announced that Apitoria Pharma Private Limited, a wholly-owned subsidiary of the Company has appointed Dr. Sanjay Chaturvedi as CEO and Ch. Venkat Nageswar as Independent Director with effect from April 4, 2023.Prior to this role, Dr.Sanjay was associated with IOL Chemicals and Pharma as Executive Director & CEO. Dr Sanjay is a Ph D in Physical Chemistry...

Telangana: Aurobindo Pharma has announced that Apitoria Pharma Private Limited, a wholly-owned subsidiary of the Company has appointed Dr. Sanjay Chaturvedi as CEO and Ch. Venkat Nageswar as Independent Director with effect from April 4, 2023.

Prior to this role, Dr.Sanjay was associated with IOL Chemicals and Pharma as Executive Director & CEO. Dr Sanjay is a Ph D in Physical Chemistry from State University of New York and Management Degree from Wharton Business School.

Mr. Venkat Nageswar retired as Deputy Managing Director, International Banking Group of State Bank of India on April 30, 2021. With over 37 years of experience spanning across various distinguished positions in the Bank pan India and abroad, he worked in all the areas of Banking - Credit, Treasury, Retail, International Banking, Finance, Risk Management etc. He has also held CFO position of the Bank for a brief period. Mr. Venkat, post superannuation, has been nominated as non-official member for Board for Trade by GOI, Member – Advisory committee of SREI Group of companies by RBI, Member – Empowered Committee to approve ECBs and ODIs by RBI. Apart from this, he is financial advisor to Indian Railway Finance Corporation and on the Boards of NCDEX, Axis MF Trustee, IDBI Capital Markets & Securities Ltd, Financial Benchmarks India Pvt. Ltd. and Svamaan Financial Services Pvt. Ltd.

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 24 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, AntiRetroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic.

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Aurobindo Pharma arm Apitoria Pharma appoints new CEO, Independent Director

Similar News